Olaparib

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

Retrieved on: 
Wednesday, August 10, 2022
Merck Group, Institute of Cancer Research, HIV disease progression rates, ATR, PARP, Drug discovery, Breast cancer, Industry, DNA repair, MD Anderson Cancer Center, NEW, The Institute, Toxicity, De novo, Research, Cancer, Neoplasm, Patient, DNA, Therapy, Institute, DDR, Associate, Netherlands Cancer Institute, Biotechnology, Olaparib, Sarah Cannon Research Institute, Safety, Francis Crick Institute, Talazoparib, List of life sciences, Novartis, Partnership, MMEJ, University, ADP, Nature Communications, Cancer Research UK, Medical director, Oncology nursing, Pharmacokinetics, Pharmaceutical industry, Medical imaging, Casting Society of America

ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.

Key Points: 
  • ART4215 is the first selective, oral, small molecule inhibitor of the Pol polymerase domain to enter the clinic.
  • Extensive preclinical studies have demonstrated that ART4215 has broad potential clinical utility, as described in Artios recent Nature Communications publication, Zatreanu et al., 2021.
  • The Pol project was originally in-licensed from Cancer Research Technology (now Cancer Research Horizons) in 2016 as part of the initial formation of Artios.
  • A recommended Phase 2 dose has been established for ART4215 in combination with talazoparib, and a randomized expansion cohort has been initiated to evaluate the combination in patients with BRCA deficient breast cancer.

Global PARP Inhibitors Cancer Therapy Market Report 2022-2028: Patent Expiration, Pricing, Dosage, Sales Analysis, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Olaparib, Fallopian tube cancer, Immunotherapy, Radiation, PARP, Company, Protein, Research, DNA repair, EMA, Lists of World Heritage Sites, Survival, PI3K, Patent, Niraparib, C1-inhibitor, Breast cancer, Peritonitis, Cancer, Indication, Rucaparib, Pancreatic cancer, Therapy, Global, Ovarian cancer, US FDA, DDR, Growth, Patient, Risk, DNA, MEK, CDK, Enzyme, Strategic planning, ADP, Pharmaceutical industry, Vaccine, Talazoparib, Carcinogenesis

The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 report is a comprehensive analysis of a variety of factors that are prevalent in the PARP Inhibitors.
  • Currently marketed PARP Inhibitors are approved for treating breast cancer, ovarian cancer, fallopian tube cancer; primary peritoneal cancer, and pancreatic cancer.
  • "Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2028" report highlights:
    Global PARP Inhibitors Cancer Therapy Market opportunity: > USD 6 Billion
    Global PARP Clinical Trials Insight by Company, Country, Indication & Phase
    Regional Analysis Based On Drug Approvals: US, Europe, China & Japan
    3.2 Significance of PARP Proteins in Tumorigenesis: Affecting Cell Division & DNA Repair

 Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Retrieved on: 
Wednesday, May 18, 2022
Nursing, Biotechnology, Professional Services, Health, Pharmaceutical, Venture Capital, Other Science, Research, Genetics, Science, Clinical Trials, Department, Cancer, GSK, Atlas, Phenotype, Genome, Disease, Population, Wellcome Trust Centre for Gene Regulation and Expression, University, Gene, University of Exeter Medical School, Medical Research Council, Multimedia, Patient, Therapy, Obesity, MRC, Nature, Twin, University College London, Genetics, Cell, Research, Type 2 diabetes, Gurdon Institute, Lists of diseases, King's College London, Statistical genetics, Probability, Life, Center, Human, Publication, Associative group analysis, Drug development, Behavior, Mutation, UK Biobank, Drug discovery, Human genetics, Olaparib, Pharmaceutical industry, Antibiotics, Science, Adrasteia

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.

Key Points: 
  • Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B.
  • Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease.
  • Combining population genetics with Adrestias synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the worlds most intractable diseases.
  • Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases.

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Retrieved on: 
Tuesday, May 3, 2022
PLOS One, Scientific Reports, CD37, Mouse, B-cell lymphoma, Mantle cell lymphoma, PARP1, Company, Non-Hodgkin lymphoma, BRCA, Olaparib, Patient, PARP2, PLOS, Lymphoid leukemia, GMP, DNA, ADP, Publication, Cell death, Radioimmunotherapy, NHL, Research, Toxic epidermal necrolysis, PARP, Cell, Risk, PET, Vaccine, Medical imaging, Medical device

OSLO, Norway, May 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL).

Key Points: 
  • 1), reports on the combined effect of Humalutin with olaparib, a member of the class of anticancer therapies known as PARP inhibitors, on NHL cell lines.
  • In the studies, the combination of Humalutin and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma).
  • both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies.
  • Separately, Nordic Nanovector reports the publication of a paper in the high-impact open access journal Scientific Reports (Ref.

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Retrieved on: 
Tuesday, May 3, 2022
PLOS One, Scientific Reports, CD37, Mouse, B-cell lymphoma, Mantle cell lymphoma, PARP1, Company, Non-Hodgkin lymphoma, BRCA, Olaparib, Patient, PARP2, PLOS, Lymphoid leukemia, GMP, DNA, ADP, Publication, Cell death, Radioimmunotherapy, NHL, Research, Toxic epidermal necrolysis, PARP, Cell, Risk, PET, Vaccine, Medical imaging, Medical device

OSLO, Norway, May 3, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL).

Key Points: 
  • 1), reports on the combined effect of Humalutin with olaparib, a member of the class of anticancer therapies known as PARP inhibitors, on NHL cell lines.
  • In the studies, the combination of Humalutin and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma).
  • both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies.
  • Separately, Nordic Nanovector reports the publication of a paper in the high-impact open access journal Scientific Reports (Ref.

Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, PDX, LinkedIn, Genome, Acute myeloid leukemia, NASDAQ, Private Securities Litigation Reform Act, PARP, DNA, Lung, Lurbinectedin, Lymphatic system, DNA repair, Clinical trial, Squamous cell carcinoma, Arsenic trioxide, CDK9, Breast, AACR, RARA, Program, American Association, Cancer, CDK2, U.S. Securities and Exchange Commission, Apoptosis, Acute promyelocytic leukemia, Workforce, Ovarian cancer, Government, Association, American Association for Cancer Research, Safety, CDK12, Olaparib, Twitter, CDK, COVID-19, Gene, CDK7, Immortalised cell line, Freedom, Annual report, Patient, Security (finance), Pharmaceutical industry, Vaccine, Syros

The data support the advancement of a development candidate from Syros CDK12 inhibitor program towards clinical development.

Key Points: 
  • The data support the advancement of a development candidate from Syros CDK12 inhibitor program towards clinical development.
  • These findings were presented in an e-poster as part of the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • CDK12 is an attractive cancer target due to its role in transcription and DNA damage repair regulation.
  • Additionally, as a single agent in in vivo cancer models this CDK12 inhibitor demonstrated tumor regressions in small cell lung cancer and breast cancer models, at well tolerated doses.

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Retrieved on: 
Saturday, March 12, 2022
MSD, Association for Molecular Pathology v. Myriad Genetics, Inc., Risk, Partnership, Guideline, Cyprus Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, AstraZeneca, Health, Precision medicine, Private Securities Litigation Reform Act, Olympia, Classification, HIV disease progression rates, Breast cancer, HER2, Biomarker, Fast Company, FDA, Olaparib, Sumathi Best Television Current Reporting Award, National Cancer Institute, DNA, Merck, Ovarian cancer, GLOBE, Patient, Neoplasm, BRCA1, NASDAQ, Myriad Genetics, SALT, PARP, BRCA2, Breast International Group, New Frontiers Science Park, MYGN, Security (finance), Genetics, Genomics, Merck & Co., Genetic testing, Technology, State, BRCA, COVID-19, Food, Diagnosis, Pharmaceutical industry, Medical imaging, Myriad

This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis CDx is intended to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2 negative high-risk early breast cancer.
  • BRACAnalysis is a companion diagnostic test that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

Adrestia Appoints Robert Johnson as Chief Executive Officer

Retrieved on: 
Thursday, March 3, 2022
Research, Venture Capital, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Lists of diseases, Genomics, Phenotype, Therapy, Leadership, Family, Business development, Patient, Research, Vaccine, List, Heart failure, Gene, Molecular biology, Drug development, Multimedia, Cancer, AAV, Disease, Johnson, Mutation, Genome, Head, Cell, University College London, GSK, Vertex Pharmaceuticals, Atlas, SR, NEA, Olaparib, Pharmaceutical industry, IND, Affinia, Adrasteia, Adrestia’s synthetic rescue platform, Adrestia, ADRESTIA’S SYNTHETIC RESCUE PLATFORM, ADRESTIA

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of life sciences executive Robert Johnson as Chief Executive Officer.

Key Points: 
  • Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of life sciences executive Robert Johnson as Chief Executive Officer.
  • Johnson joins the company following executive positions at Boston-based gene therapy company Affinia Therapeutics, which he co-founded, and a career in biotech and pharmaceutical management consulting.
  • Johnson will lead Adrestia in the next phase of its development, leveraging its leading synthetic rescue platform to advance a portfolio of first-in-class therapeutics into clinical studies.
  • Robert Johnson was previously co-founder and Chief Business Officer of Affinia Therapeutics, a Boston-based gene therapy company engineering next-generation AAV capsids.

First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

Retrieved on: 
Wednesday, December 15, 2021
Olaparib, Mesothelioma, Hospital, Orphan drug, Nordic Society for Invention and Discovery, CD4, FDA, PFS, European Society of Gynaecological Oncology, Clinical trial, Cancer, Diagnosis, Growth, IIB, Innovation Norway, Industry, Progression-free survival, AstraZeneca, Science, Gynecologic cancer disparities in the United States, European Network for the Investigation of Gender Incongruence, Oncology, Norway, Head, Melanoma, OSE, Reverse transcriptase, Research, Neoplasm, Patient, Immune system, PD-L1, PARP, Ovarian cancer, Usha Menon, Fast Track, TET, NSCLC, Ipilimumab, BRCA, Large-cell lung carcinoma, Pharmaceutical industry, Phase

Innovation Norway has granted Ultimovacs NOK 10 million (approximately $1.2 million) to support the execution of the Phase II DOVACC study.

Key Points: 
  • Innovation Norway has granted Ultimovacs NOK 10 million (approximately $1.2 million) to support the execution of the Phase II DOVACC study.
  • DOVACC is one of five randomized Phase II clinical trials of Ultimovacs' telomerase vaccine UV1 in combination with other immunotherapies.
  • UV1 is being investigated in combination with checkpoint inhibitors in Phase II trials covering advanced malignant melanoma, ovarian cancer, head and neck squamous cell carcinoma, malignant pleural mesothelioma, and non-small cell lung cancer (NSCLC).
  • The trial is designed to evaluate Ultimovacs proprietary UV1 cancer vaccine in combination with AstraZenecas durvalumab, a PD-L1 checkpoint inhibitor and its PARP inhibitor, olaparib, the maintenance therapy for advanced ovarian cancer.

LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

Retrieved on: 
Tuesday, November 30, 2021
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Patient, Safety, Cancer, Merck, Death, Shanda, Nominal interest rate, Prescription Drug User Fee Act, Recurrence, Priority review, AstraZeneca, Breast cancer, New Drug Application, Risk, BRCA, Olaparib, FDA, Food and Drug Administration Amendments Act of 2007, Merck & Co., Food, Tf–idf, Pharmaceutical industry

The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.

Key Points: 
  • The safety and tolerability profile of LYNPARZA in this trial was in line with that observed in prior clinical trials.
  • LYNPARZA is a targeted treatment option for metastatic breast cancer patients with an inherited BRCA mutation.
  • AstraZeneca with Merck continue to research LYNPARZA in early and metastatic breast cancer patients with a BRCA mutation.
  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).